HEL358.1
The cell line is not validated yet.
UHi030-A
General
iPSC Line |
|
| hPSCreg name | UHi030-A |
| Cite as: | UHi030-A |
| Alternative name(s) |
HEL358.1
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 6th July 2026 |
| Notes | There are a total of 7 iPSC lines derived from women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as PCOS, and 7 BMI‑matched healthy controls without PMOS/PCOS. |
| User feedback | |
Provider |
|
| Generator | University of Helsinki (UH) |
| Owner | University of Oulu and Oulu University Hospital |
| Distributors | |
| Derivation country | Finland |
External iPSC Databases |
|
| BioSamples | SAMEA120138595 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
Additional restrictions:
Upon agreement between all parties, MTA required |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Non-disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Data available on request upon MTA agreement ( masuma.khatun@helsinki.fi) |
External Databases (Donor) |
|
| BioSamples | SAMEA120138595 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Alueellinen lääketieteellinen tutkimuseettinen toimikunta (Regional Medical Research Ethics Committee of Pohjois‑Pohjanmaan hyvinvointialue) |
| Approval number | EETTMK: 58/2026 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Alueellinen lääketieteellinen tutkimuseettinen toimikunta (Regional Medical Research Ethics Committee of Pohjois‑Pohjanmaan hyvinvointialue) |
| Approval number | EETTMK: 58/2026 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
iPSC Derivation
General |
|
| Source cell line name | Endometrial Stromal Fibroblast |
| Source cell type |
A stromal cell of the endometrium, characterized by its fibroblast-like morphology, regenerative capacity, and ability to undergo decidualization. It differentiates into a decidual stromal cell during pregnancy, essential for embryo implantation and maintenance. This cell is involved in tissue proliferation, remodeling, and breakdown, responding to hormonal changes, particularly estrogen and progesterone.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | CRISPRa genome activation |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | OriP sequence of the episomal vector used for the CRISPRa reprogramming |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | iPSC morphology assessment |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Yes |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | Yes |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
||||
| SOX2 |
Yes |
|
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.